GSK says new data support filing of once weekly treatment for diabetes


LONDON — GlaxoSmithKline will push ahead with plans to file its experimental once-weekly diabetes drug albiglutide for regulatory approval, following the read-out from a series of clinical trials. Albiglutide belongs to the same class of injectable GLP-1 medicines as Novo Nordisk’s Victoza and Byetta, from Amylin Pharmaceuticals and Eli Lilly. Byetta was the first drug of the type.

Last November, GSK reported that albiglutide cut blood sugar less than daily Victoza in the first of a series of late-stage clinical trials, dimming its prospects in an increasingly competitive market.

However, the company said on Tuesday that top-line data from seven of eight Phase III clinical studies had now been received and, taken together, the results supported progression of the medicine towards regulatory filings in type-2 diabetes.